Strategy for the borderline resectable pancreatic cancer using neo-adjuvant chemoradiation therapy

s / Pancreatology 13 (2013) S1–S80 S10 group (1 yr; 85.8%, 3 yrs; 56.7%) and ODP group (1 yr; 79.3%, 3 yrs; 44.5%). (P 1⁄4 0.079) Conclusions: There seems to be increasing evidence that LDP is equivalent to ODP for Pancreatic cancer in terms of oncologic outcome. However, long term oncologic result will be required and further randomized prospective studies should be performed to support the validity of LDP for Pancreatic cancer.